Compare Iron Mountain Inc (IRM) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Mesoblast Limited — how do they compare? Iron Mountain Inc trades at $114.22 (market cap $34.46B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Iron Mountain Inc is far larger — about 19.7× Mesoblast Limited's market cap, and Iron Mountain Inc pays a 2.99% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Mesoblast Limited for 14 Days on average.
| IRM | MESO | |
|---|---|---|
Market Cap | $34.46B | $1.75B |
Volume | 1,379,608 | 239,027 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $20.96 |
52-Week Low | $78.86 | $13.19 |
Typical Hold Time | 80 Days | 14 Days |
Enterprise Value | $53.87B | $1.83B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong analyst consensus. The company reported revenue growth to $6.90B in 2025, though net income margin compressed to 2.09%. Recent news highlights expansion in data centers and digital partnerships, while institutional investors like Bank of America and California State Teachers Retirement System increased holdings significantly in Q2 2026.
The outlook remains positive with a consensus price target of $142.75 implying 23% upside, supported by data center pipeline growth and digital cross-selling. Key risks include high debt levels with a debt-to-asset ratio of 79.04% in 2025 and margin pressure from rising interest expenses. Earnings beats in recent quarters reinforce execution strength, but valuation multiples like a P/E of 82.09 demand sustained growth.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
